Literature DB >> 1594223

Intraocular recurrence of uveal melanoma after proton beam irradiation.

E S Gragoudas1, K M Egan, J M Seddon, S M Walsh, J E Munzenrider.   

Abstract

The authors evaluated tumor recurrence as an end point in 1077 uveal melanoma patients treated by proton beam irradiation between 1975 and 1987, with a mean follow-up of 4.0 years. Twenty tumors (1.9%) exhibited definitive growth between 4 months and 66 months after irradiation (median, 19 months): 10 were marginal recurrences, 5 were ring melanomas, 3 were uncontrolled tumors, and 2 were extrascleral extensions. Ten of these eyes were enucleated without further intervention, 2 patients died of metastases soon after the growth was detected, and 8 patients had further conservative therapy. In 5 other patients, tumor growth was suspected but unconfirmed and the eye was enucleated elsewhere; the 5-year probability of local tumor control based on 25 recurrences was 97% +/- 1%. There was a nonsignificant increase in the rate of metastases among patients with documented tumor recurrence (adjusted relative risk, 1.5; 95% confidence interval, 0.66 to 3.4). Results suggest that recurrence of uveal melanomas treated by proton beam therapy is uncommon, but that treatment failure may increase risk of death from metastasis.

Entities:  

Mesh:

Year:  1992        PMID: 1594223     DOI: 10.1016/s0161-6420(92)31900-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  12 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Endoresection of choroidal melanoma.

Authors:  B Damato; C Groenewald; J McGalliard; D Wong
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

3.  Long-term follow-up after uveal melanoma charged particle therapy.

Authors:  D H Char; S M Kroll; J Castro
Journal:  Trans Am Ophthalmol Soc       Date:  1997

4.  Development and validation of a patient based measure of outcome in ocular melanoma.

Authors:  A J Foss; D L Lamping; S Schroter; J Hungerford
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

5.  Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma.

Authors:  A J Foss; I Whelehan; J L Hungerford; D F Anderson; R D Errington; A Kacperek; M Restori; J Kongerud; M Sheen
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

6.  Risk factors for metastatic uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

7.  Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment.

Authors:  A Klingenstein; C Fürweger; A K Mühlhofer; S F Leicht; U C Schaller; A Muacevic; B Wowra; C Hintschich; K H Eibl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-16       Impact factor: 3.117

Review 8.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

9.  Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.

Authors:  Evangelos S Gragoudas; Anne Marie Lane; John Munzenrider; Kathleen M Egan; Wenjun Li
Journal:  Trans Am Ophthalmol Soc       Date:  2002

10.  [Endoresection following proton beam irradiation of large uveal melanomas].

Authors:  N E Bechrakis; S Höcht; P Martus; K M Kreusel; J Heese; M H Foerster
Journal:  Ophthalmologe       Date:  2004-04       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.